The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment.

As the public’s interest in COVID-19 products continues to wane and the autoimmune medicine Humira settles into life without exclusivity, the anti-cancer agent Keytruda is set to rule the drug marketplace for years to come.

It’s summer 2023. By now, many of us have “emerged”, as they say. We are getting out and about and making up for the lost time of the past three years. And much of this progress is thanks to the COVID-19 vaccines and treatments from Pfizer, BioNTech, and Moderna, which played a major role in helping us put the pandemic in the rearview mirror.

The company is leaning on Mounjaro, approved last May in the U.S. for diabetes, to soften the hit from insulin price cuts and competition for cancer therapy Alimta.

The suit claims the companies “downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro” and never warned patients about the possibility of gastroparesis—a slowdown or stopping of the digestive system—or gastroenteritis, an infection and inflammation of the digestive system.

People taking popular diabetes and weight loss drugs such as Novo Nordisk’s Ozempic and Wegovy or Eli Lilly’s Mounjaro should temporarily stop taking them before having elective surgery to avoid possible serious complications, the American Society of Anesthesiologists (ASA) said on Thursday.

The National Institute for Health and Care Excellence (NICE) in its draft guidance said it asked the company for more data on whether the drug Mounjaro, also known as tirzepatide, resulted in better weight loss than other drugs belonging to the same class of treatments.

Eli Lilly’s recently registered Phase IIIb SURMOUNT-5 trial will compare its Mounjaro with Novo Nordisk’s Wegovy in obese or overweight patients with weight-related health conditions.

The global health body is first revising guidelines for treating children and adolescents with obesity, and will then update recommendations for adults, said Francesco Branca, WHO director of nutrition and food safety.

Eli Lilly and Co. on Thursday raised its annual revenue and profit forecasts after topping first-quarter sales estimates on demand for its closely watched diabetes drug Mounjaro, ahead of a decision on its use as a treatment for obesity.